Abrupt Discontinuation of the Codman Hepatic Artery Infusion Pump: Considerations in the Era of Precision Medicine

American College of Surgeons
Abrupt Discontinuation of the Codman Hepatic Artery Infusion Pump: Considerations in the Era of Precision Medicine
As development of personalized and precision therapies accelerates, an increasing number of treatments will be targeted at small patient populations. Research and development in rare diseases has been supported for decades by initiatives such as the Orphan Drug Act and the Safe Medical Devices Act, which provide protections and regulatory considerations for therapies designed for uncommon indications. Nonetheless, these treatments are a challenging economic proposition for manufacturers, who often resort to high prices to offset costs of therapies servicing small patient groups.
Source: American College of Surgeons

Geef een reactie

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *